Event Abstract Back to Event Anti-arthritic potential of Ardisia crispa root (Myrsinaceae) in vitro and in vivo Joan A. Blin1, Roslida Abd Hamid1*, Yoke Kqueen Cheah1 and Razana Mohd Ali2 1 Department of Biomedical Sciences, Faculty of Medicine and Health sciences, University of Putra Malaysia, Malaysia 2 Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Malaysia Background Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory joint disease characterised by excessive angiogenesis. Anti-angiogenesis could be a promising therapeutic strategy against RA. Ardisia crispa or “Mata Itik” is a local plant traditionally used for treating various illnesses. Its properties like anti-tumour, anti-inflammatory and anti-angiogenic have been reported in previous studies. However, its anti-angiogenic role against RA has yet to be investigated. Thus, the present study investigated the anti-angiogenic potential of hexane extract (ACRH), quinone rich fraction (QRF), and benzoquinone (BQ) isolated from the roots of the plant using cell-based assays in vitro. ACRH was also tested against in vivo model. Methods Cytotoxicity, tube formation, cell invasion, and cell apoptosis assays were performed using human umbilical vein endothelial cells (HUVEC) and human fibroblast-like synoviocytes for rheumatoid arthritis cells (HFLS-RA). In vivo study was performed using collagen-induced arthritis (CIA) in rats. Results ACRH, QRF and BQ were highly cytotoxic against HUVEC (IC50 at 1.9 ± 0.2, 2.5 ± 0.8 and 1.7 ± 0.2 µg/mL, respectively). Nevertheless, ACRH and QRF were found to be less cytotoxic against HFLS-RA cell (4.0 ± 2.3 and 5.7 ± 0.9 µg/mL, respectively) after 24 hours of exposure. Interestingly, BQ remained highly cytotoxic against HFLS-RA cells with IC50 at 1.6 ± 0.5 µg/mL. All samples (0.05, 0.5 and 5 µg/mL) significantly (P<0.05) inhibited VEGF-induced HUVEC tube formation and IL-1β-induced HFLS-RA cell invasion in a concentration-dependent manner. Both ACRH and BQ exhibited late apoptotic activity in IL-1β-induced HFLS-RA cells at highest concentration (5 µg/mL). For CIA in rats, all doses of ACRH (10, 30, 100 mg/kg) showed significance reduction of ankle joint diameter, paw volume, and arthritic scoring. Conclusion This study had uncovered the anti-angiogenic effect of Ardisia crispa root in suppressing angiogenesis against both HUVEC and HFLS-RA cells, even though its role in modulating angiogenic biomarkers in RA animal model has yet to be determined. Acknowledgements The present work were financially supported by Fundamental Research Grant Scheme (FRGS/2/2014/SKK10/UPM/02/1) and Geran Putra IPS (GPIPS9576500). Keywords: Ardisia crispa root, Human Umbilical Vein Endothelial Cells (HUVEC), human fibroblast-like synoviocytes for rheumatoid arthritis cells (HFLS-RA), Rheumatoid arthritis, Angiogenesis, Collagen-induced arthritis rat Conference: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”, Putrajaya, Malaysia, 3 Dec - 5 Feb, 2019. Presentation Type: Oral Presentation Topic: Inflammatory diseases Citation: Blin JA, Abd Hamid R, Cheah Y and Mohd Ali R (2019). Anti-arthritic potential of Ardisia crispa root (Myrsinaceae) in vitro and in vivo. Front. Pharmacol. Conference Abstract: International Conference on Drug Discovery and Translational Medicine 2018 (ICDDTM '18) “Seizing Opportunities and Addressing Challenges of Precision Medicine”. doi: 10.3389/conf.fphar.2018.63.00011 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 03 Oct 2018; Published Online: 17 Jan 2019. * Correspondence: Dr. Roslida Abd Hamid, Department of Biomedical Sciences, Faculty of Medicine and Health sciences, University of Putra Malaysia, Kuala Lumpur, Malaysia, roslida@upm.edu.my Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Joan A Blin Roslida Abd Hamid Yoke Kqueen Cheah Razana Mohd Ali Google Joan A Blin Roslida Abd Hamid Yoke Kqueen Cheah Razana Mohd Ali Google Scholar Joan A Blin Roslida Abd Hamid Yoke Kqueen Cheah Razana Mohd Ali PubMed Joan A Blin Roslida Abd Hamid Yoke Kqueen Cheah Razana Mohd Ali Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.